People are increasingly aware of the benefits and applications of GLP-1agonists in managing diabetes and obesity
500 Additionally, PepGens PGN-EDO51, designed to skip exon 51 in the DMD gene, has shown promising results in Phase I clinical trials and is now in Phase II (NCT06079736)
The EMPA-KIDNEY Collaborative Group, Herrington WG, Staplin N, Wanner C, Green JB, Hauske SJ, et al
Treatment and Follow-Up Glutathione therapy occurs through regular self-administered injections
The 1 mg presentation provides a standardized research quantity suitable for cell culture experiments, biochemical assays, and comparative growth factor studies